IRONWOOD PHARMACEUTICALS, INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate of 1.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate · last filed 2025-03-31
- IRONWOOD PHARMACEUTICALS, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2024 was 1.00%.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 6 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 12 month |
|---|---|---|
| 2024-12-31 | 1.00% 10-K · filed 2025-03-31 | |
| 2023-12-31 | 1.50% 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |